NOT KNOWN FACTUAL STATEMENTS ABOUT IL-2 THERAPY FOR MELANOMA

An individual point mutation, V6A, released in to the molecule greatly improved the toxicity profile and diminished VLS when compared to the WT molecule [76]. More research and clinical trials might be necessary to ascertain if this modified build has enhanced protection and efficacy in individuals.Tregs: T regulatory cells; TME: tumor microenviron